Bearish
Pfizer's stock declines 1.25% to $28.45 amid profit-taking and valuation concerns.
Pfizer's stock experienced a 1.25% decline to $28.45, attributed to profit-taking and valuation concerns. Despite recent positive developments, such as FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation, the stock's recent rally toward a 52-week high led to a pullback.
Key points
- Profit-taking and valuation concerns lead to a 1.25% decline in Pfizer's stock price.
- FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation.
Sources
AI-generated from public news sources. Not financial advice.
